Universal Beteiligungs und Servicegesellschaft mbH Makes New $57,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 10,829 shares of the company’s stock, valued at approximately $57,000.

Several other institutional investors also recently added to or reduced their stakes in RXRX. GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after buying an additional 2,026 shares during the period. NewEdge Advisors LLC increased its position in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after buying an additional 2,387 shares during the period. GF Fund Management CO. LTD. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $54,000. San Luis Wealth Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at approximately $54,000. Finally, ADG Wealth Management Group LLC bought a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at approximately $55,000. 89.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and an average target price of $7.00.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX opened at $5.53 on Wednesday. The business’s fifty day moving average price is $5.34 and its two-hundred day moving average price is $5.93. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -3.12 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company had revenue of $19.10 million during the quarter, compared to the consensus estimate of $15.38 million. During the same quarter last year, the company earned ($0.40) earnings per share. The business’s revenue was up 33.3% on a year-over-year basis. As a group, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.